Blue Water Vaccines Appoints Jay Newmark as Chief Medical Officer By Investing.com

Blue Water Biotech, Inc. (BWV), a biotechnology company spanning multiple sectors, today announced the appointment of Jay Newmark, M.D., MBA as the Company’s Chief Medical Officer.

Dr. Newmark is a board-certified urologist with over 30 years of experience managing Men’s Health issues, including benign prostatic hyperplasia (“BPH”). Blue Water currently owns ENTADFI®, an FDA-approved treatment for BPH that counteracts negative sexual side effects seen in men on alternative BPH therapies. Dr. Newmark’s appointment will support Blue Water’s upcoming launch of ENTADFI® and he will work closely with Blue Water management to ensure BPH patients are able to receive proper access to treatment.

In addition to his extensive medical training and experience in urology private practice, Dr. Newmark has a strong background in commercial product development in the Men’s Health sector. Previously, Dr. Newmark served as Chief Medical Officer at Clarus Therapeutics, Inc., where he was integral to the launch of JATENZO® and other Men’s Health initiatives. He has also worked on advanced detection technologies for prostate cancer at Genomic Health Inc. and OPKO Health Inc.

“I am thrilled to join the Blue Water team and provide my expertise as we prepare to launch ENTADFI® to support patients with BPH,” said Dr. Newmark. “Millions of men suffer from BPH symptoms each year and many of those men are faced with frustrating sexual side effects as a result of their BPH medication. We look forward to supporting new BPH patients with ENTADFI® as well as provide current patients a novel option to address BPH symptoms without sacrificing sexual performance as we see with other current therapies.”

“The addition of Dr. Newmark to the Blue Water team is a critical and exciting step in the execution of our commercial strategy for ENTADFI®,” said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water. “As we prepare to make this product available to men with BPH across the country, we will rely heavily on his knowledge and experience to support our commercial operation and our patients. We are confident that his expertise both in the medical field as a urologist and in the product development space will be invaluable moving forward through launch and beyond.”

Dr. Newmark received his M.D. from the University of Michigan Medical School and completed his residency in urology at the Johns Hopkins Hospital. He also holds a Master of Business Administration from the University of Chicago.

Dr. Newmark will join Blue Water management at the upcoming American Urological Association Annual Meeting 2023 from April 18th through May 1st in Chicago, Illinois. Blue Water will be available during the conference for one-on-one meetings and can be found at booth 439. Interested parties may request a one-on-one meeting at [email protected] or contact Blue Water at (513) 620-4101.